Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Advances in the Management of Menopausal Symptoms, Fertility Preservation, and Bone Health for Women With Breast Cancer on Endocrine Therapy
This study aims to provide an updated overview of the available approaches for improving the QoL of patients with breast cancer receiving estrogen deprivation therapy, focusing on advances in the management of menopausal symptoms, including sexual dysfunction, fertility preservation, and bone health.PMID:37229618 | DOI:10.1200/EDBK_390442
Source: Clinical Genitourinary Cancer - May 25, 2023 Category: Cancer & Oncology Authors: Matteo Lambertini Luca Arecco Terri Lynn Woodard Audrey Messelt Kristin E Rojas Source Type: research
To Radiate or Not to Radiate After Breast-Conserving Surgery-Endocrine Therapy is the Question
Ann Surg Oncol. 2023 May 23. doi: 10.1245/s10434-023-13665-3. Online ahead of print.NO ABSTRACTPMID:37219655 | DOI:10.1245/s10434-023-13665-3
Source: Ann Oncol - May 23, 2023 Category: Cancer & Oncology Authors: Sumana Narayanan Roshni Rao Source Type: research
Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan
CONCLUSIONS: In a routine clinical practice setting in Japan, patients with HR + , HER2- MBC appear to benefit from abemaciclib treatment in terms of treatment response and median PFS, with the results broadly reflecting the evidence demonstrated in clinical trials.PMID:37217763 | DOI:10.1007/s12282-023-01461-6
Source: Breast Cancer - May 22, 2023 Category: Cancer & Oncology Authors: K Nozawa M Terada M Onishi Y Ozaki T Takano W Fakhouri D Novick J M Haro L H Faris T Kawaguchi Y Tanizawa Junji Tsurutani Source Type: research
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial
CONCLUSION: In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2- MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.PMID:37207300 | DOI:10.1200/JCO.22.02392
Source: Clinical Genitourinary Cancer - May 19, 2023 Category: Cancer & Oncology Authors: Kevin Kalinsky Melissa K Accordino Codruta Chiuzan Prabhjot S Mundi Elizabeth Sakach Claire Sathe Heejoon Ahn Meghna S Trivedi Yelena Novik Amy Tiersten George Raptis Lea N Baer Sun Y Oh Amelia B Zelnak Kari B Wisinski Eleni Andreopoulou William J Gradish Source Type: research
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
CONCLUSIONS: PreCycle is the first multicenter randomized eHealth trial demonstrating a significant benefit for MBC patients receiving oral tumor therapy when using an interactive autonomous patient empowerment application.PMID:37201751 | DOI:10.1016/j.annonc.2023.05.003
Source: Ann Oncol - May 18, 2023 Category: Cancer & Oncology Authors: N Harbeck P A Fasching R W ürstlein T Degenhardt D L üftner R E Kates J Schumacher P R äth O Hoffmann R Lorenz T Decker M Reinisch T G öhler P Staib O Gluz T Schink öthe M Schmidt AGO-B WSG PreCycle investigators Source Type: research
A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
CONCLUSIONS: Our multiparameter classifier differentially identifies patients who may benefit from HER2-targeted therapy alone from those who need chemotherapy and predicts pCR to anti-HER2 therapy alone comparable to chemotherapy plus dual anti-HER2 therapy in unselected patients.PMID:37195235 | DOI:10.1158/1078-0432.CCR-22-3753
Source: Clinical Cancer Research - May 17, 2023 Category: Cancer & Oncology Authors: Jamunarani Veeraraghavan Carolina Gutierrez Carmine De Angelis Robert Davis Tao Wang Tomas Pascual Pier Selenica Katherine Sanchez Hiroaki Nitta Monesh Kapadia Anne C Pavlick Patricia Galv án Brent Rexer Andres Forero-Torres Rita Nanda Anna M Storniolo I Source Type: research
